Sign In


Kamalakannan Palanichamy PhD

Kamalakannan Palanichamy PhD
Research Asst ProfessorCollege of MedicineKamalakannan.palanichamy@osumc.edu
385E Wiseman Hall 400 W 12th Avenue Columbus OH 43210
Phone:614-247-6393Fax: 614-292-5435
  • Experimental Therapeutics

General Research Interest

(1) Identifying Underlying Mechanisms of Radiation Resistance in Treatment Refractory Tumors. (2) Cancer Stem Cells (3) Exploiting Protein-Protein Interactions at Transcriptional and Translational Level and Identifying New Therapeutic Targets (4) Integrative OMICS

Current Publications

  • Waters JD, Sanchez C, Sahin A, Futalan D, Gonda DD, Scheer JK, Akers J, Palanichamy K, Waterman P, Chakravarti A, Weissleder R, Morse B, Marsh N, Furfine E, Chen CC, Carvajal I, Carter BSCT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.J Neurooncol 110(1) 37-48 10/1/2012
  • Estrada-Bernal A, Palanichamy K, Ray Chaudhury A, Van Brocklyn JRInduction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.Neuro Oncol 14(4) 405-15 4/1/2012
  • Palanichamy K, Sreejayan N, Ontko ACOvercoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes.J Inorg Biochem 106(1) 32-42 1/1/2012
  • Kim TH, Song J, Alcantara Llaguno SR, Murnan E, Liyanarachchi S, Palanichamy K, Yi JY, Viapiano MS, Nakano I, Yoon SO, Wu H, Parada LF, Kwon CSuppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth.PLoS One 7(8) e42818 1/1/2012